6287 search
Myriad Genetics
NASDAQ MYGN 28,12 US$ 46,92%
Logo

IHS Markit Score Update: Drop in demand for ETFs holding Myriad Genetics Inc is a negative sign for its shares

Publié le 10 août 2017

View photos

According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however.

Credit worthiness

Credit default swap

CDS data is not available for this security.

Please send all inquiries related to the report to score@ihsmarkit.com.

Charts and report PDFs will only be available for 30 days after publishing.

This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

Les autres articles de la compagnie
Top Analyst Upgrades and Downgrades: Amazon, Blackstone, Fir
What Do Hedge Funds Think of World Fuel Services Corporation
Is Myriad Genetics, Inc. (MYGN) A Good Stock To Buy?
3 Underdog Stocks That Warren Buffett Would Love
[$$] Myriad Genetics' Profit Rises on Higher Sales of DNA Te
Articles en illimité et contenus premium Je m'abonne
Editoriaux
et Nouvelles
Actions
Minières
Or et
Argent
Marchés La Cote
search 6287
search